Clinical trial
Bevacizumab in Treating Patients With Myelodysplastic Syndrome
NCT00022048 · Stanford University, Other · Completed
Key facts
| NCT number | NCT00022048 |
|---|---|
| Title | Bevacizumab in Treating Patients With Myelodysplastic Syndrome |
| Official title | Safety and Efficacy Trial of Bevacizumab: Anti-VEGF Humanized Monoclonal Antibody (NSC 704865) Therapy for Myelodysplastic Syndrome (MDS) |
| Lead sponsor | Stanford University, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms |
| Intervention type | Biological |
| Interventions | bevacizumab |
| Start date | Aug 1, 2001 |
| Completion | Nov 1, 2004 |
| First posted | Jan 27, 2003 |
| Last update posted | May 15, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: